Nephrology, Dialysis, Transplantation

Sepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2 Diabetes

By Yu-Yang Tseng, Hsien-Yi Wang, Jui-Yi Chen, Min-Hsiang Chuang

Cohort study of 21,035 peopleInterventions

The paper

Yu-Yang Tseng, Hsien-Yi Wang, Jui-Yi Chen, Min-Hsiang Chuang

Chi Mei Medical Center

Nephrology, Dialysis, Transplantation, 7 Aug 2026

doi.org/10.1093/ndt/gfag175 PubMed 42566276

Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk